MetrioPharm Presents Clinical Phase IIa Psoriasis Study Data at the 5th WPPAC in Stockholm
Zurich, June 26, 2018. MetrioPharm AG, a clinical stage pharmaceutical biotech company developing new medications against chronic immune disorders, today announced that clinical Phase IIa data obtained from patients with moderate to severe plaque psoriasis will be presented at the 5th World Psoriasis & Psoriatic Arthritis Conference (WPPAC) in Stockholm.
The poster presentation details are as follows:
- Title: The macrophage modulator MP1032 shows safety and efficacy in a human phase IIa study for the treatment of moderate-to-severe plaque psoriasis
- Poster-ID: 035
- Presented by: Dr. Petra Schulz, Senior Project Manager Drug Development
- Date: 28-30 June 2018
- Location: Stockholm Waterfront Congress Centre, Stockholm, Sweden
Every three years, the International Federation of Psoriasis Associations (IFPA) organizes the WPPAC, a conference for medical professionals from all over the world to present their latest developments in psoriasis and psoriatic arthritis research.
Psoriasis is a chronic-relapsing, inflammatory autoimmune dermatosis, which is often manifested as plaque psoriasis. A global report published by the world health organization (WHO) in 2016 describes psoriasis as one of the major health burdens worldwide and highlights the need for new, tolerable, and effective medications.
At the WPPAC, MetrioPharm, represented by Dr. Petra Schulz, will present clinical data of the completed Phase IIa psoriasis study. In this randomized, double-blind, parallel, and placebo-controlled trial, 46 patients with moderate-to-severe plaque psoriasis were treated twice daily with 100 mg MP1032. After only six weeks of treatment, MP1032 reduced the PASI scores by about 28 % in patients who entered the study with moderate psoriasis. Furthermore, the excellent safety profile of MP1032 was confirmed in this trial. Dr. Petra Schulz commented "This makes us look forward to the results of our Phase II study that is currently running in 14 study centers over Germany as well as Poland and is expected to be finalized in the first quarter of 2019."
MP1032 is the lead compound of a class of proprietary immune modulators developed by MetrioPharm. MP1032 is believed to modulate the oxidative stress-mediated activation state of macrophages and downregulate the M1 state. In contrast to other immune-modulating and disease-modifying drugs, MP1032 does not impact T-cells and preferentially affects macrophages at the sites of inflammation. MP1032 has shown anti-inflammatory activity in animal models of disease and a favorable toxicology profile in pre-clinical studies.
MetrioPharm AG is a pharmaceutical biotech company developing drug compounds for the treatment of autoimmune and other inflammatory diseases. MetrioPharm's MP1000 pipeline consists of small molecule immune modulators for unmet medical needs in Immune-Mediated Inflammatory Diseases (IMIDs).
MetrioPharm AG was founded in 2007 and is headquartered in Zurich with research facilities in Berlin.
This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm's assessment as of the date of this release. Such forward-looking statements are neither promises nor guarantees, but are subject to numerous risks and uncertainties, many of which are beyond MetrioPharm's control, that could cause actual results to differ materially from those contemplated in these forward-looking statements. MetrioPharm does not assume any obligation to update forward-looking statements with respect to changed expectations or new events, conditions or circumstances on which these statements are based. A liability or guarantee and, if applicable, claims for topicality, correctness and completeness of these data and information are excluded and cannot be derived either explicitly or impliedly.